{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:42:45Z","timestamp":1778863365362,"version":"3.51.4"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"am","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.pbb.2023.173588","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T02:06:13Z","timestamp":1687226773000},"page":"173588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Anxiolytic-like effects of an mGluR 5 antagonist and a mGluR 2\/3 agonist, and antidepressant-like effects of an mGluR 7 agonist in the chick social separation stress test, a dual-drug screening model of treatment-resistant depression"],"prefix":"10.1016","volume":"227-228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-0368","authenticated-orcid":false,"given":"Stephen W.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendolyn D.","family":"Squires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sequioa J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendolyn M.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Sufka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Rimoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama S.","family":"Gadepalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0006-3223(99)00159-6","article-title":"Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study","volume":"47","author":"Auer","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.pbb.2023.173588_bb0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.euroneuro.2006.03.002","article-title":"Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests","volume":"17","author":"Belozertseva","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.pbb.2023.173588_bb0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00004850-200511000-00001","article-title":"Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740","volume":"20","author":"Bergink","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.pbb.2023.173588_bb0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2008.06.089","article-title":"Behavioral characterization of the mGlu group II\/III receptor antagonist, LY-341495, in animal models of anxiety and depression","volume":"592","author":"Bespalov","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2003.10.009","article-title":"MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity","volume":"46","author":"Chaki","year":"2004","journal-title":"Neuropharmacology"},{"issue":"43","key":"10.1016\/j.pbb.2023.173588_bb0035","doi-asserted-by":"crossref","first-page":"15653","DOI":"10.1073\/pnas.0507901102","article-title":"Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression","volume":"102","author":"Choudary","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.pbb.2023.173588_bb0040","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1176\/appi.ajp.2011.09111607","article-title":"Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study","volume":"168","author":"Deschwanden","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.pbb.2023.173588_bb0045","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2023.173588_bb0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0193-953X(05)70283-5","article-title":"Definition and epidemiology of treatment-resistant depression","volume":"19","author":"Fava","year":"1996","journal-title":"Psychiatric Clin. North Am."},{"issue":"6","key":"10.1016\/j.pbb.2023.173588_bb0055","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pbb.2023.173588_bb0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00213-005-2227-1","article-title":"Screening antidepressants in the chick separation-stress paradigm","volume":"181","author":"Feltenstein","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2023.173588_bb0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pbb.2003.10.019","article-title":"The chick separation-stress paradigm: A validation study","volume":"77","author":"Feltenstein","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2023.173588_bb0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpsychires.2018.02.006","article-title":"Anxiolytic effects of ascorbic acid and ketamine in mice","volume":"100","author":"Fraga","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"16","key":"10.1016\/j.pbb.2023.173588_bb0075","doi-asserted-by":"crossref","first-page":"10975","DOI":"10.1074\/jbc.M113.542654","article-title":"Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior","volume":"289","author":"Gee","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.pbb.2023.173588_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","article-title":"Alpha-2 adrenergic receptor agonists: a review of current clinical applications","volume":"62","author":"Giovannitti","year":"2015","journal-title":"Anesthesia progress"},{"issue":"10","key":"10.1016\/j.pbb.2023.173588_bb0090","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0269881117705089","article-title":"Ketamine\u2019s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders","volume":"31","author":"Glue","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pbb.2023.173588_bb0095","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0269881119874457","article-title":"Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study","volume":"34","author":"Glue","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00213-003-1444-8","article-title":"Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans","volume":"168","author":"Grillon","year":"2003","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.pbb.2023.173588_bb0110","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.biopsych.2007.03.017","article-title":"Increased levels of glutamate in brains from patients with mood disorders","volume":"62","author":"Hashimoto","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2023.173588_bb0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuropharm.2011.06.009","article-title":"Pharmacological reversal of cognitive bias in the chick anxiety-depression model","volume":"62","author":"Hymel","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2023.173588_bb0120","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.physbeh.2013.07.013","article-title":"Strain vulnerability and resiliency in the chick anxiety-depression model","volume":"120","author":"Hymel","year":"2013","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.pbb.2023.173588_bb0125","series-title":"The Cochrane Database of Systematic Reviews","first-page":"CD010828","article-title":"Azapirones versus placebo for panic disorder in adults","volume":"vol. 9","author":"Imai","year":"2014"},{"key":"10.1016\/j.pbb.2023.173588_bb0130","series-title":"The Clinical and Quantitative EEG Effects and Plasma Levels of Fenobam (McN-3377) in Subjects with Anxiety: An Open Rising Dose Tolerance and Efficacy Study","author":"Itil","year":"1978"},{"issue":"3","key":"10.1016\/j.pbb.2023.173588_bb1000","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1124\/jpet.112.200915","article-title":"ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization","volume":"344","author":"Kalinichev","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.pbb.2023.173588_bb0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173588_bb0140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pbb.2013.03.017","article-title":"Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats","volume":"107","author":"Koike","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2023.173588_bb0145","first-page":"95","article-title":"Fenobam: another anxiolytic?","volume":"31","author":"Lapierre","year":"1982","journal-title":"Curr. Ther. Res."},{"issue":"8","key":"10.1016\/j.pbb.2023.173588_bb0150","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0028-3908(00)00194-5","article-title":"Antidepressant-like actions of an AMPA receptor potentiator (LY392098)","volume":"40","author":"Li","year":"2001","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2023.173588_bb0155","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00213-004-2098-x","article-title":"Anxiolytic-like activity of the mGLU2\/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice","volume":"179","author":"Linden","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2023.173588_bb0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbr.2013.01.045","article-title":"Brain-derived neurotrophic factor response in vulnerable and resilient genetic lines in the chick anxiety-depression model","volume":"245","author":"Loria","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb0165","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2023.173588_bb0170","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.neuropharm.2007.10.020","article-title":"Synergism between fluoxetine and the mGlu2\/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis","volume":"54","author":"Matrisciano","year":"2008","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb0175","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/jm9606756","volume":"40","author":"Monn","year":"1997","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.pbb.2023.173588_bb0180","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1073\/pnas.1216100110","article-title":"L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors","volume":"110","author":"Nasca","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.pbb.2023.173588_bb0185","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.pbb.2023.173588_bb0190","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000353198","article-title":"Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis","volume":"82","author":"Offidani","year":"2013","journal-title":"Psychother. Psychosom."},{"issue":"2","key":"10.1016\/j.pbb.2023.173588_bb0195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuropharm.2003.09.006","article-title":"Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats","volume":"46","author":"Pa\u0142ucha","year":"2004","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb0200","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.pbb.2005.06.015","article-title":"Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist","volume":"81","author":"Pa\u0142ucha","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb0205","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00213-007-0856-2","article-title":"Activation of the mGlu7 receptor elicits antidepressant-like effects in mice","volume":"194","author":"Palucha","year":"2007","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2023.173588_bb0210","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1124\/jpet.110.169730","article-title":"The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N\u2019-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent","volume":"334","author":"Pa\u0142ucha-Poniewiera","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2023.173588_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110239","article-title":"The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL\/6J mice","volume":"109","author":"Pa\u0142ucha-Poniewiera","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2023.173588_bb0220","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00004714-198204000-00010","article-title":"Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study","volume":"2","author":"Pecknold","year":"1982","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pbb.2023.173588_bb0225","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0925-4927(03)00003-9","article-title":"Effective electroconvulsive therapy reverses glutamate\/glutamine deficit in the left anterior cingulum of unipolar depressed patients","volume":"122","author":"Pfleiderer","year":"2003","journal-title":"Psychiatry Res."},{"issue":"15\u201316","key":"10.1016\/j.pbb.2023.173588_bb0230","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1007\/s00213-016-4325-7","article-title":"Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats","volume":"233","author":"Podkowa","year":"2016","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.pbb.2023.173588_bb0235","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamapsychiatry.2016.0838","article-title":"Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial","volume":"73","author":"Quiroz","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pbb.2023.173588_bb0240","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.28970","article-title":"A randomized, double-blind, controlled phase II study of Foliglurax in Parkinson\u2019s disease","volume":"37","author":"Rascol","year":"2022","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.pbb.2023.173588_bb0245","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1037\/0735-7028.35.1.74","article-title":"Current issues in anxiety and depression: comorbid, mixed, and subthreshold disorders","volume":"35","author":"Rivas-Vazquez","year":"2004","journal-title":"Prof. Psychol. Res. Pract."},{"issue":"12","key":"10.1016\/j.pbb.2023.173588_bb0250","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology: official publication of the American college of","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2023.173588_bb0255","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-007-0758-3","article-title":"In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2\/3 receptor agonist LY404039 in animal models of psychiatric disorders","volume":"193","author":"Rorick-Kehn","year":"2007","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.pbb.2023.173588_bb0260","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173588_bb2000","series-title":"The principles of humane experimental technique","author":"Russell","year":"1959"},{"key":"10.1016\/j.pbb.2023.173588_bb0265","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.brainres.2010.12.007","article-title":"Cognitive bias in the chick anxiety-depression model","volume":"1373","author":"Salmeto","year":"2011","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.pbb.2023.173588_bb0270","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/archpsyc.61.7.705","article-title":"Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression","volume":"61","author":"Sanacora","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.pbb.2023.173588_bb0275","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/da.22536","article-title":"A review of ketamine abuse and diversion","volume":"33","author":"Sassano-Higgins","year":"2016","journal-title":"Depress. Anxiety"},{"issue":"3","key":"10.1016\/j.pbb.2023.173588_bb0280","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/1025389031000146773","article-title":"LY354740, an mGlu2\/3 receptor agonist as a novel approach to treat anxiety\/stress","volume":"6","author":"Schoepp","year":"2003","journal-title":"Stress (Amsterdam, Netherlands)"},{"issue":"1\u20133","key":"10.1016\/j.pbb.2023.173588_bb0285","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejphar.2004.08.016","article-title":"Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test","volume":"501","author":"Shimazaki","year":"2004","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2023.173588_bb0290","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ijnp\/pyx108","article-title":"Lack of antidepressant effects of (2R,6R)-Hydroxynorketamine in a rat learned helplessness model: comparison with (R)-Ketamine","volume":"21","author":"Shirayama","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5\u20136","key":"10.1016\/j.pbb.2023.173588_bb0295","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/FBP.0b013e32830cd839","article-title":"Selective activation of metabotropic G-protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission","volume":"19","author":"Stachowicz","year":"2008","journal-title":"Behav. Pharmacol."},{"issue":"9","key":"10.1016\/j.pbb.2023.173588_bb0300","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ajem.2007.12.005","article-title":"Adverse events associated with ketamine for procedural sedation in adults","volume":"26","author":"Strayer","year":"2008","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.pbb.2023.173588_bb0305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pbb.2013.10.013","article-title":"Identification of a treatment-resistant, ketamine-sensitive genetic line in the chick anxiety-depression model","volume":"113","author":"Sufka","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"8","key":"10.1016\/j.pbb.2023.173588_bb0310","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/FBP.0b013e3280115fac","article-title":"Modeling the anxiety-depression continuum hypothesis in domestic fowl chicks","volume":"17","author":"Sufka","year":"2006","journal-title":"Behav. Pharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2023.173588_bb0315","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/FBP.0b013e32832a8082","article-title":"Antidepressant efficacy screening of novel targets in the chick anxiety-depression model","volume":"20","author":"Sufka","year":"2009","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173588_bb0320","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.bjp.0703923","article-title":"Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective, and systemically active mGlu5 receptor antagonist","volume":"132","author":"Tatarczy\u0144ska","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2023.173588_bb0325","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0091-3057(02)00850-X","article-title":"The anxiolytic action of mGlu2\/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam","volume":"73","author":"Tizzano","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2023.173588_bb0330","article-title":"Randomized, double-blind, placebo-controlled trial of the mglu2\/3 negative allosteric modulator decoglurant in partially refractory major depressive disorder","volume":"81 (4), 18m1247","author":"Umbricht","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.pbb.2023.173588_bb0335","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1037\/0735-7044.116.6.1075","article-title":"Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats","volume":"116","author":"Walker","year":"2002","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.pbb.2023.173588_bb0340","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.fbp.0000236269.87547.9d","article-title":"Modeling anxiety-like states: pharmacological characterization of the chick separation stress paradigm","volume":"17","author":"Warnick","year":"2006","journal-title":"Behav. Pharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2023.173588_bb0345","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/0269881108089805","article-title":"Modelling the anxiety-depression continuum in chicks","volume":"23","author":"Warnick","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pbb.2023.173588_bb0350","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1037\/1064-1297.4.4.347","article-title":"Chlordiazepoxide reverses social-separation-induced distress vocalizations and analgesia in young domestic fowl","volume":"4","author":"Watson","year":"1996","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb3000","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1037\/0021-843X.114.4.522","article-title":"Rethinking the mood and anxiety disorders: a quantitative hierarchical model for DSM-V","volume":"114","author":"Watson","year":"2005","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.pbb.2023.173588_bb0355","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1037\/1064-1297.7.2.83","article-title":"Benzodiazepine receptor function in the chick social-separation-stress procedure","volume":"7","author":"Watson","year":"1999","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2023.173588_bb0360","series-title":"Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives","first-page":"3","article-title":"Behavioural models in psychopharmacology","author":"Willner","year":"1991"},{"issue":"19","key":"10.1016\/j.pbb.2023.173588_bb0365","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1007\/s00213-015-4034-7","article-title":"Treatment-resistant depression: are animal models of depression fit for purpose?","volume":"232","author":"Willner","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2023.173588_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173446","article-title":"Clinical investigations of compounds targeting metabotropic glutamate receptors","volume":"219","author":"Witkin","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb0375","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/17512433.2023.2198703","article-title":"Clinical pharmacological innovation in the treatment of depression","volume":"16","author":"Witkin","year":"2023","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173588_bb0380","author":"World Health Organization"},{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb0385","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00213-006-0390-7","article-title":"An mGluR2\/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats","volume":"186","author":"Yoshimizu","year":"2006","journal-title":"Psychopharmacology"},{"issue":"7604","key":"10.1016\/j.pbb.2023.173588_bb0390","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pbb.2023.173588_bb0395","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.pbb.2023.173588_bb0400","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2023.173588_bb0405","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00213-014-3697-9","article-title":"Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder","volume":"232","author":"Zhang","year":"2015","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.pbb.2023.173588_bb0410","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eurpsy.2013.10.005","article-title":"Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex","volume":"29","author":"Zhou","year":"2014","journal-title":"Eur. Psychiatry"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305723000758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305723000758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:46:37Z","timestamp":1758775597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305723000758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":83,"alternative-id":["S0091305723000758"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2023.173588","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anxiolytic-like effects of an mGluR 5 antagonist and a mGluR 2\/3 agonist, and antidepressant-like effects of an mGluR 7 agonist in the chick social separation stress test, a dual-drug screening model of treatment-resistant depression","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2023.173588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"173588"}}